MEchanisms of Resistance in EGFR Mutated Nonpretreated Advanced Lung Cancer Receiving OSimErtib

NCT03865511 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

150

Enrollment

OTHER

Sponsor class

Conditions

Non-small Cell Lung Cancer

Interventions

DRUG: TAGRISSO® 80mg (Osimertinib)
GENETIC: Tumor biopsies
GENETIC: ctDNA analysis

Sponsor

Nantes University Hospital

Collaborators

[object Object]